CurrentRheuma
Get Weekly

Topic · page 46 of 47

Lupus & antiphospholipid syndrome

Systemic and cutaneous lupus erythematosus, lupus nephritis, neuropsychiatric lupus, disease activity, remission and low disease activity, damage, antimalarials and targeted treatment; antiphospholipid antibodies and antiphospholipid syndrome, thrombotic and obstetric

Briefs 1,801–1,840 of 1,848 placed here, newest publication first

Briefs in Lupus & antiphospholipid syndrome

Newest publication first

  1. J Rheumatol

    The Effect of Psychiatric Comorbidity on Healthcare Utilization for Youth With Newly Diagnosed Systemic Lupus Erythematosus

    Cohort study

  2. Arthritis Care Res (Hoboken)

    Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population‐Based Study

    Cohort study

  3. Rheumatology (Oxford)

    SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis

    Mechanistic study

  4. Ann Rheum Dis

    3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus

    Mechanistic study

  5. Arthritis Care Res (Hoboken)

    Posttraumatic Stress Disorder and Risk of Systemic Lupus Erythematosus Among Medicaid Recipients

    Case-control study

  6. Arthritis Care Res (Hoboken)

    Comprehension, Utility, and Acceptability of a Multidomain Physical Functioning Report for Systemic Lupus Erythematosus Patients and Their Providers

    Cross-sectional study

  7. Rheumatology (Oxford)

    Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials

    Secondary analysis

  8. Rheumatology (Oxford)

    Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study

    Cohort study

  9. Arthritis Care Res (Hoboken)

    Use of Popular Opinion Leader Models to Disseminate Information About Clinical Trials to Black Individuals With Lupus in Two US Cities

    Research article

  10. Rheumatology (Oxford)

    Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus

    Cohort study

  11. J Rheumatol

    Age-Stratified 30-day Rehospitalization and Mortality and Predictors of Rehospitalization Among Patients With Systemic Lupus Erythematosus: A Medicare Cohort Study

    Cohort study

  12. Arthritis Care Res (Hoboken)

    Race, Ethnicity, and Disparities in the Risk of End‐Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort

    Cohort study

  13. Rheumatology (Oxford)

    Antiphospholipid antibodies in patients with calcific aortic valve stenosis

    Case-control study

  14. Rheumatology (Oxford)

    Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort

    Cross-sectional study

  15. Rheumatology (Oxford)

    Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis

    Diagnostic or prognostic study

  16. Clin Exp Rheumatol

    CD56brightCD16- to CD57+CD56dimCD16+ NK cell ratio discriminates disease activity and renal involvement in patients with systemic lupus erythematosus

    Cross-sectional study

  17. Rheumatology (Oxford)

    Risk of adverse pregnancy outcomes prior to the onset of an autoimmune rheumatic disease: a systematic review

    Meta-analysis

  18. J Rheumatol

    Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities

    Cohort study

  19. Clin Exp Rheumatol

    Deep remission within 12 months prevents renal flare and damage accrual in lupus nephritis

    Cohort study

  20. Rheumatology (Oxford)

    Predictors and prognostic stratification for lupus low disease activity state: results from a prospective clinical trial

    Cohort study

  21. Rheumatology (Oxford)

    COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study

    Cohort study

  22. Rheumatology (Oxford)

    Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico

    Cohort study

  23. Rheumatology (Oxford)

    Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine

    Cohort study

  24. Scand J Rheumatol

    Patients with laboratory criteria of anti-phospholipid syndrome and ‘non-criteria’ manifestations: a multicenter cohort

    Cohort study

  25. Rheumatology (Oxford)

    Circulating and renal fibrocytes are associated with interstitial fibrosis in lupus nephritis

    Mechanistic study

  26. Rheumatology (Oxford)

    Resting state functional connectivity in SLE patients and association with cognitive impairment and blood–brain barrier permeability

    Cross-sectional study

  27. Rheumatology (Oxford)

    The BILAG-2004 index is associated with development of new damage in SLE

    Cohort study

  28. Rheumatology (Oxford)

    Trajectories of depressive symptoms in systemic lupus erythematosus over time

    Cohort study

  29. Rheumatology (Oxford)

    Severe Libman–Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases

    Cohort study

  30. Rheumatology (Oxford)

    Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE

    Cross-sectional study

  31. Rheumatology (Oxford)

    Cancer occurrence after SLE: effects of medication-related factors, disease-related factors and survival from an observational study

    Case-control study

  32. Clin Exp Rheumatol

    SERPINA1 and plasminogen as novel biomarkers in obstetric antiphospholipid syndrome patients

    Research article

  33. Clin Exp Rheumatol

    Early recognition of catastrophic antiphospholipid syndrome in patients with antiphospholipid syndrome based on a Chinese cohort study

    Cohort study

  34. Clin Exp Rheumatol

    Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control study

    Case-control study

  35. Clin Exp Rheumatol

    Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE

    Cohort study

  36. Clin Exp Rheumatol

    Increased risk of hospital admissions in patients with active systemic lupus erythematosus (SLE) classified according to two different SLE disease activity indices: a prospective cohort study

    Cohort study

  37. Clin Exp Rheumatol

    A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome

    Cohort study

  38. Clin Exp Rheumatol

    Anti-SSA/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases

    Cohort study

  39. Clin Exp Rheumatol

    Decreased perforin-producing B cells correlate with systemic lupus erythematosus

    Mechanistic study

  40. Clin Exp Rheumatol

    Primary antiphospholipid syndrome as a cause of impaired left ventricular diastolic function: experience from a Serbian cohort

    Cross-sectional study

All 1,848 Briefs in ExploreShowing Briefs 1,801–1,840 of 1,848, newest first